Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling.
BACKGROUND
Cartilage degeneration often occurs after osteosynthesis of a devascularized intermediary fragment in a joint fracture, in mosaicplasty or in whole-joint toe-to-finger transplantation. Hypothetically, the degeneration is secondary to a collapse of the transferred subchondral bone as it remodels during high mechanical load. Bisphosphonates are used to reduce resorption of necrotic bone. We tested a systemic pretreatment before harvesting the graft in order to protect the bone and cartilage against collapse and secondary arthrosis.


METHODS
Rats were given one zoledronate injection and bone grafts were harvested. The grafts were frozen, thawed and placed into bone chambers, and implanted into another batch of rats. Graft resorption and new bone formation was measured by histomorphometric analysis and compared with untreated grafts.


RESULTS
In the remodeled area of the controls, the graft was almost totally resorbed and replaced by bone marrow. In the zoledronate-treated specimens, the graft remained and the graft trabeculas were lined with new bone. By histomorphometry, the total amount of bone (graft plus new bone) within the remodeled area was 16% in the zoledronate-treated grafts and 5% in the controls (p = 0.003).


CONCLUSIONS
A bone graft can be pretreated with bisphosphonate and remain protected against resorption once implanted again.
Tägil
Magnus
M
Department of Orthopedics, Lund University Hospital. SE-221 85 Lund, Linköping, Sweden. magnus.tagil@ort.lu.se
Aspenberg
Per
P
Astrand
Jörgen
J
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000473:pathology / Q000517:prevention & control*; D016025:Bone Transplantation / Q000379:methods / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid